HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.
HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.